Acute hepatitis due to the hepatitisC virus: Where are the transmission occurring? / Infección aguda por el virus de la hepatitisC: ¿en qué personas se está produciendo la transmisión?

OBJECTIVE: To know the transmission patterns of the acute infection by the hepatitisC virus at a time when we are close to its elimination. PATIENTS AND METHODS: A prospective descriptive clinical-epidemiological study of cases of acute HCV infection diagnosed between 2016 and 2020 was carried out in a reference hospital in the island of Gran Canaria. RESULTS: Twenty-two cases of acute HCV were diagnosed (10 primary infections and 12 reinfections). There was an increase in the incidence from 0.6 in 2016 and 2017 to 2.3 cases per 100,000 inhabitants in 2020. The median age was 46years. From these, 77.3% were men and 68.2% were HIV-positive. According to the risk factors, 54.5% had high-risk sexual practices, 83.3% were men who had sex with men (70% with a concomitant STI), 31.8% were drug users, 9.1% were women with neuropsychiatric disorders, and one woman (4.5%) had a previous surgical intervention. There were thirteen patients (40.9%) who presented symptoms and eleven out of the thirteen patients who were asymptomatic were HIV-positive. CONCLUSIONS: An increase in incidence was observed in the last years of the study and the main route of infection was high-risk sexual practice, mainly in men who have sex with men and who are HIV positive. Cases related to unsafe sex in other non-HIV groups are probably under-diagnosed. Microelimination strategies may not be sufficient to diagnose these cases, so in order to achieve elimination of the HCV the best strategy would be a population-based screening.

Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis.

BACKGROUND: Acute hepatitis C virus (AHC) infection is increasingly common among HIV+ men who have sex with men (MSM). Until 2017, the guidelines recommended therapy with pegylated-interferon plus ribavirin with a mild sustained virological response (SVR). This prompted many patients to reject that treatment, at that time, waiting to be treated with better and safer options with new Direct-Acting-Antivirals (DAA). OBJECTIVES: Assess the efficacy and safety of Elbasvir/Grazoprevir to treat recent chronic hepatitis C infection, genotype 1 or 4, in HIV+ MSM patients. METHODS: Prospective, open-labeled, two center, pilot study. SVR is analyzed for treatment with Elbasvir/Grazoprevir (8 weeks in GT1b or 12 in GT1a or GT4) in patients with a recent chronic HCV infection, defined as HCV infection lasting less than 4 years and mild liver fibrosis (liver stiffness <8kPa). RESULTS: Forty-eight patients were included (May 2017-March 2018): 2 GT1b, 24 GT1a and 22 GT4. HCV-RNA>800000UI in 63% and medium liver stiffness 4.9kPa. The SVR was 98%, one patient failed due to poor adherence. 67% of patients had adverse effects, but only 16% treatment related. The most frequent side effects were gastrointestinal (19%), related with the central nervous system (18%), respiratory (16%) and systemic symptoms (15%). During one year of follow-up post-therapy, 4 AHC and 18 patients with sexually transmitted diseases (STD) were diagnosed. CONCLUSIONS: Treatment with Elbasvir/Grazoprevir in this scenario is highly effective and safe. Patients with risky sexual practices must remain linked to the medical care system to detect new STD and HCV reinfection.

Hepatitis C virus acquisition among Egyptians: analysis of a 10-year surveillance of acute hepatitis C.

OBJECTIVE: To identify current risk factors for hepatitis C virus (HCV) acquisition among Egyptians. METHODS: Patients with acute HCV were identified through a surveillance system of acute hepatitis in four fever hospitals in Egypt between 2002 and 2012. Case-control analysis was conducted, cases being incident acute symptomatic HCV and controls being acute hepatitis A identified at the same hospitals. The questionnaire covered iatrogenic, community and household exposures to HCV in the 1-6 months prior to onset of symptoms. Multivariate models were built to identify risk factors associated with HCV acquisition among non-drug users and drug users separately. RESULTS: Among non-drug users, hospital admission was independently associated with acute HCV infection (OR = 4.2, 95% CI = 1.7-10.5). Several iatrogenic procedures, for example admission in a surgery unit, sutures, IV injections and IV infusions, highly correlated with hospital admission, were also associated with acute HCV infection and could have been used in the final model instead of hospital admission. Among drug users, identified risk factors were multiple sexual relations (OR = 4.0, 95% CI = 1.1-14.7), intravenous drug use (OR = 3.9, 95% CI = 1.2-13.0) and shaving at the barbershops (OR = 8.7, 95% CI = 2.4-31.4). Illiteracy and marriage were significant risk factors in both groups. CONCLUSION: Invasive medical procedures are still a major risk for acquiring new HCV infections in Egypt, as is illicit drug use in spreading HCV infection.

Descripción de hallazgos virológicos inusuales en hepatitis C aguda / Unusual virologic findings in acute hepatitis C

La hepatitis C aguda es asintomática o inespecífica en un 80 % de los casos, por lo que su diagnóstico suele pasar inadvertido, con escasas descripciones de evolución y manejo en la literatura. El clearance es-pontáneo se produce sólo en el 20 %, ocurriendo en general, dentro de las 12 semanas desde la infección. Las guías clínicas recomiendan un mínimo de seguimiento de 12-16 semanas antes de considerar tra-tamiento antiviral. Se describen dos casos de nuestra consulta donde se logró detectar la recaída virológica, al extender el tiempo de segui-miento

Acute hepatitis C is a diagnostic challenge because it is asymptomatic or non specific in more than 80% of cases. There is limited data on the literature, because of its low incidence. Spontaneous clearance is observed only in 20% of cases, generally within the first 12 weeks. Clinical guidelines, recommend to wait at least 12-16 weeks before considering antiviral treatment. In the following cases at our consultation, we managed to diagnose the viral breakthrough by extending the follow-up period.

Acute hepatitis C infection with unclear route of transmission / Infección aguda de hepatitis C sin vía clara de trasmisión

A 43-year old man acquired acute hepatitis C virus (HCV) infection with unclear route of transmission. There were no known sexual or other risk factors for HCV acquisition. Phylogenetic analysis confirmed that the case was infected with identical genotype 1b strain. After symptomatic treatment for three weeks, the HCV was spontaneously cleared and liver function recovered.

Un hombre de 43 anos adquirió la infección del virus de la hepatitis aguda tipo C (VHC) por una via de trasmisión incierta. No habia ningún factor de riesgo sexual u otro conocido para la adquisición del VHC. El análisis filogenético confirmó que el caso se infectó con una cepa 1b de genotipo idéntico. Tras del tratamiento sintomático por tres semanas, el VHC se eliminó espontáneamente y lafunción del higado fue recuperada.

Hepatitis C aguda: Acute hepatitis C

La hepatitis C aguda es una enfermedad generalmente subclínica, de ahí que no se incluya en el diagnóstico diferencial de los pacientes con un cuadro agudo. Además diagnosticarla presenta dificultades ya que los anticuerpos contra el virus tardan en aparecer, pudiendo ser negativos cuando el paciente manifiesta los síntomas; en este punto la enfermedad podría diagnosticarse con el RNA viral, pero éste no es fácil que sea solicitado inicialmente. Se presenta un paciente que ingresó por una hepatitis aguda en el que se descartaron causas virales como hepatitis A-B, Ebstein Barr, Citomegalovirus (CMV) hepatitis autoinmune, hepatotoxicidad y enfermedad hipoxicoisquémica, que explicaran la sintomatología y los hallazgos bioquímicos del paciente, en quien se demostró seroconversión contra el virus de la hepatitis C asociado a una carga viral elevada. Todo lo anterior es consistente con un diagnóstico de hepatitis C aguda. Se describe el manejo del paciente y las características de la enfermedad.

Acute hepatitis C is usually a sub-clinical disease, thus it is not included in the differential diagnosis of patients with acute disease. Making the diagnosis is also difficult because the virus antibodies appear at later stages and many even be negative even if the patient has symptoms; at this point the diagnosis of the disease could be made with the viral RNA, but it is not easy to ask for it initially. A patient is admitted because of acute hepatitis where viral causes such as hepatitis A-B, Epstein Barr, Cytomegalovirus (CMV), auto-immune hepatitis, hepatoxitiy and hypoxic-isquemic disease, that would explain the symptoms and bio-chemical findings were discarded. The patient’s seroconversion against Hepatitis C virus associated to a high viral load was demonstrated. All this is consistent with an acute Hepatitis C diagnosis. Patient’s management and disease characteristics are described. (Acta Med Colomb 2008; 33: 28-32).